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Safety testing1There are now numerous in vitro and in silico ADME alternatives to in vivo assays but how do different
industries incorporate them into their decision tree approaches for risk assessment, bearing in mind that
the chemicals tested are intended for widely varying purposes? The extent of the use of animal tests is
mainly driven by regulations or by the lack of a suitable in vitro model. Therefore, what considerations
are needed for alternative models and how can they be improved so that they can be used as part of
the risk assessment process? To address these issues, the European Partnership for Alternative
Approaches to Animal Testing (EPAA) working group on prioritisation, promotion and implementation
of the 3Rs research held a workshop in November, 2008 in Duesseldorf, Germany. Participants included
different industry sectors such as pharmaceuticals, cosmetics, industrial- and agro-chemicals. This report
describes the outcome of the discussions and recommendations (a) to reduce the number of animals used
for determining the ADME properties of chemicals and (b) for considerations and actions regarding
in vitro and in silico assays. These included: standardisation and promotion of in vitro assays so that they
may become accepted by regulators; increased availability of industry in vivo kinetic data for a central
database to increase the power of in silico predictions; expansion of the applicability domains of
in vitro and in silico tools (which are not necessarily more applicable or even exclusive to one particular
sector) and continued collaborations between regulators, academia and industry. A recommended imme-
diate course of action was to establish an expert panel of users, developers and regulators to deﬁne the
testing scope of models for different chemical classes. It was agreed by all participants that improvement
and harmonization of alternative approaches is needed for all sectors and this will most effectively be
achieved by stakeholders from different sectors sharing data.
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Evaluation of the rates and extents of absorption, distribution,
metabolism, and excretion (ADME) of compounds is a fundamental
part of the in-depth understanding of the toxicological and phar-
macological effects they may exert on humans and animals. Tradi-
tionally, ADME studies have been carried out using animals and,
for certain industrial sectors, in vivo studies still have to be per-
formed according to European regulatory frameworks. However,
the development of non-animal test methods (i.e. ‘‘alternative’’ as-
says which may include in silico and in vitromodels, as well as deci-
sion tree strategies to reduce animal testing) is strongly promoted
within all industrial sectors in order to produce safety data that are
more relevant to humans and to replace animal studies currently
in use (Horizontal Legislation, 2008, agro-chemicals EU regulation:
Council Directive 91/414 revision). The urgency for the cosmetic
industry is more imminent since the use of certain in vivo animal
studies (e.g. genotoxicity, eye and skin irritation and acute toxicity)
has already been banned due to the 7th Amendment to the Cos-
metics Directive and in vivo ADME studies will be banned in 2013.
In vitro biotransformation assays have been used routinely for
decades but none have been validated for risk analysis (Blaauboer
et al., 1994; Coecke et al., 1999). Nevertheless, the value of in vitro
assays in assessment of chemicals is exempliﬁed by their use in the
drug candidate selection process in the pharmaceuticals industry
which has proved quite successful in providing estimates of human
bioavailability and clearance (Cai et al., 2006). The Organisation for
Economic Co-operation and Development Technical Guideline
(OECD) TG 428 describes an in vitro assay for testing dermal
absorption but no similar detailed Guidelines exist with respect
to the use of sub-cellular fractions, primary cells and in silicometh-
ods to predict metabolism (biotransformation). Nevertheless,
tiered testing strategies for assessing metabolism have been sug-
gested and reviewed previously (ECVAM, 2002; Coecke et al.,
2005a). Models used to identify ADME properties (as well as or-
gan-speciﬁc toxicities of chemicals) are summarised in Table 1, to-
gether with information regarding recommendations by the
regulatory authorities and validation status. There is also a number
of Quantitative Structure Activity Relationship (QSAR) models that
are available to both industry and academia and these include but
are not limited to the OECD toolbox (Table 2). Supporting activities
from industry, European Commission and Academia to enable the
development of non-animal models are summarised in Table 3.
An EPAA workshop was held in Duesseldorf on 24th/25th
November, 2008, and was attended by scientiﬁc experts in the
pharmaceutical, chemical, pesticide and cosmetic industries, by
regulators, as well as by academia. Participants included represen-
tatives of the Scientiﬁc Committee on Consumer Safety (SCCS),
European Centre for the Validation of Alternative Methods (EC-
VAM), European Food Safety Authority (EFSA) and Directorate Gen-
eral (DG) for Research. The aim of the workshop was to discuss
how to implement in vitro ADME test systems as part of Integrated
Testing Strategies (ITS) for the testing of cosmetics, pharmaceuti-
cals and industrial chemicals and pesticides (including agro-chem-
icals such as herbicides, fungicides, or insecticides). The present
report presents the outcome of the break-out group discussions
in describing how in vitro assays may be used within different
industry sectors and how regulators view in vitro data. It also out-
lines international projects aimed at developing alternative test
models. In addition, the break-out sessions discussed the suitabil-
ity of in vitro approaches to systemic toxicity and hazard identiﬁ-
cation for target organs and steps required to attain regulatory
acceptance. Emphasis is placed on in vitro assays and their use in
risk assessment issues including preliminary risk assessment such
as for prioritisation and deprioritisation, rather than in targetedrisk assessment per se, since this is markedly different between
industry sectors and is out of the scope of this paper.2. Regulatory framework and views from regulators
The use of animal assays is different across industries, whereby
in vivo studies are required in one sector but banned in another. An
overview of these differences and the agencies which affect the use
of animals is described below.
2.1. Pharmaceuticals
The European Medicines Agency (also known as the EMA) is a
European agency which evaluates pharmaceuticals. In the USA,
the equivalent agency is the Food and Drug Administration
(FDA). Both the EMA and FDA evaluate and monitor products, as
well as developing technical guidance (and guidance documents)
and providing scientiﬁc advice to sponsors. According to EU Direc-
tives (EU Directive 65/65/EEC, 1965 and subsequent amendments),
in order to bring a drug onto the market and before it has even
been tested ‘‘ﬁrst in man’’ its safety should be tested in animals
– with the exception of certain genotoxicity tests (e.g. Ames assay).
The Directive recommended that the use of animals should be lim-
ited for ethical and animal protection and welfare reasons and ef-
forts should be made to develop new techniques which would
produce the same quality of information as in vivo studies. It was
for this reason that ECVAM was created in 1992, following a Com-
munication from the Commission to the Council and the Parlia-
ment in October 1991. The requirement in Directive 86/609/EEC
was to protect animals used for experimental and other scientiﬁc
purposes and to actively support the development, validation
and acceptance of methods which could reduce, reﬁne or replace
the use of laboratory animals. Therefore, although the pharmaceu-
tical industry continues to develop new non-animal assays, this
industry has not been pressured by regulators into switching from
in vivo assays to in vitro alternatives to test drugs during the devel-
opment process.
2.2. Chemicals
EU Chemicals Agency (ECHA) is the agency which manages the
technical, scientiﬁc and administrative aspects of the Registration,
Evaluation, Authorisation and Restriction of Chemicals (REACH)
regulation. The REACH regulation came into effect in June 2007
and was designed to regulate the manufacture, import, marketing
and use of industrial chemicals (including ingredients used for for-
mulations regulated otherwise such as pesticides and cosmetics).
Manufacturers, importers and downstream users must demon-
strate that the manufacture/import/use of a substance does not ad-
versely affect human health and that risks are adequately
controlled. This applies only to chemicals that are produced and/
or imported in volumes of 1 tonne or more per year and it was ex-
pected to apply to tens of thousands of existing and new chemicals
but over 143,000 chemical substances marketed in the European
Union were pre-registered by the 1 December 2008 deadline
(http://echa.europa.eu/sief_en.asp; Hartung and Rovida, 2009).
The need for determining the toxicokinetics (TK) proﬁle is listed
in Annex 1 (Section 1.0.2) of the legislation but in Annexes (VII–
X) it is not speciﬁcally required and its consideration is needed
only if these data are available (Annex VIII–X). However, REACH
does provide guidance (guidance on information requirements
and chemical safety assessment, Chapters R.7C and R.8) on the
use of TK for selection of dose, route of administration and test-
species, as well as on route-to-route extrapolation in the derivation
Table 1
In vitro models used for identifying ADME and speciﬁc organ toxicity.
Endpoint Organ Model Comments
Absorption
Intestinal absorption, P-gp
efﬂux
Intestine Caco-2 cells (Hubatsch et al., 2007) Validated for prediction of substrates or inhibitors of P-
glycoprotein (Elsby et al., 2008)
MDCK (Irvine et al., 1999) Absorption values may vary, depending on multiple factors
(culture, passage etc.)
PAMPA membrane, artiﬁcial lipid layers (Avdeef et al.,
2005)
New model validated as more predictive than PAMPA
model (Chen et al., 2008)
Dermal absorption Skin Human skin static or ﬂow-through diffusion cell models,
using (partly) standardized in vitro conditions and human,
rat or pig skin
OECD and EU guidelines are available (EU SANCO 222 and
OECD TG 428, SCCS/1358/10)
Absorption across the BBB Blood:brain
barrier
Brain microvascular endothelial cells (Porcine, bovine), cell
lines, artiﬁcial lipid layers (Garberg et al., 2005; Prieto et al.,
2004)
No single model predictive, a battery of tests recommended
(Garberg et al., 2005; Prieto et al., 2004)
Metabolism
Metabolite proﬁle Liver Microsomes, S9, hepatocyte suspensions and cultures Ubiquitously used by industry. Their use for drug
metabolism is reviewed by Bjornsson et al., 2003
Skin Human keratinocytes, HaCaT cells, ex vivo human skin Used to determine presence of metabolites. The skin
contains detoxiﬁcation enzymes such as N-acetyl
transferases (Goebel et al., 2009) but also expresses FMOs
and CYPs (Janmohamed et al., 2001)
Clearance Liver Recombinant systems (human CYPs expressed in E. coli,
baculovirus), hepatic sub-cellular fractions (S9 or liver
microsomes), hepatocytes in primary cultures or
suspension, liver slices
Recombinant CYPs suitable for ‘‘frontline’’ predictive
human metabolism studies in early drug discovery
(McGinnity and Riley, 2001). All liver-derived models
provide useful information for prediction of metabolic
routes, rates and interactions (Pelkonen et al., 2001)
Induction Liver Hepatocytes (e.g. human primary cultures) (Shou et al.,
2008)
FDA, 2006 guideline recommends either fresh or
cryopreserved human hepatocytes for this assay (FDA,
2006)Nuclear hormone receptor binding and activation (e.g. PXR)
(Cui et al., 2008)
Cell lines, e.g. LS180 (Harmsen et al., 2008)
Inhibition Liver Microsomes (from pools of >20 donors), hepatocyte
suspensions and cultures, recombinant systems (e.g.
human CYPs)
FDA recommends the use of microsomes but hepatocyte
assays are in development (to study transporter effects and
phase 2 metabolism) (FDA, 2006)
Excretion
Excretion Kidney,
liver
Primary proximal tubule cell lines (Liang et al., 1999) At present there is no model to reliably predict biliary or
renal excretionPrimary human hepatocyte sandwich cultures (Bi et al.,
2006)
Toxicity
Phototoxicity Skin NRU Balb 3T3 photocytotoxicity (Spielmann et al., 1998) Validated since 2000, in annex V of directive 67/548; OECD
432 since 2002
Corrosivity Skin Trans-electrical resistance (TER) test (Archer and Liebisch,
1998)
Validated since 2003; OECD TG 430
Human reconstructed skin models (Spielmann et al., 2007) Regulatory accepted for skin corrosion, using MTT as the
endpoint (OECD TG 431, ESAC, 2000)
In vitro membrane barrier test (Corrositex™ Membrane) Validated since 2007; OECD TG 435.
Skin irritation Skin EpiSkin™ and EpiDerm™ reconstructed skin models
(Spielmann et al., 2007)
EpiSkin is expected to be endorsed as full replacement of
the in vivo test OECD TG 431. EpiSkin™, Skinethic™ and
EpiDerm™ are validated stand-alone replacements for the
rabbit Draize test, distinguishing between skin irritating
(R38) and non-irritating (no-label) chemicals (ESAC, 2008)
Skin Sensitisation Skin A combination of skin penetration, protein or peptide
binding assays, activation of dendritic-like cells or cell lines
Sens-it-iv program initiated in 2005
Eye irritation Eye Bovine Corneal Opacity and Permeability (BCOP) (OECD
437); Isolated Chicken Eye test (OECD 438) assay
Partial replacements for the in vivo rabbit eye irritation test.
Recommended by the OECD for use as part of a tiered
testing strategy for classiﬁcation and labelling within a
speciﬁc applicability domain
Mutagenicity In vitro test battery (Kirkland et al., 2005): Ames assay
(OECD TG 471); chromosomal aberration (OECD TG 473);
in vitro micronucleus test (OECD Draft TG 487); mouse
lymphoma thymidine kinase
SCCP recommended a test battery for cosmetic ingredients
(SCCP/1005/06)
Carcinogenicity SHE (LeBoeuf et al., 1996) and Balb/c 3T3 (Maeshima et al.,
2009) cell transformation assays
OECD TG 495
Reproductive toxicity EST assay (ESAC, 2001; Bremer et al., 2002) ReproTex program initiated in 2005
Neurotoxicity Brain and
CNS
Organotypic cultures derived from undifferentiated
embryonic brain or spinal cord tissue (Braun et al., 2006)
Models which reﬂect speciﬁc but not all processes in vivo
neural development. Based on mechanistic processes
in vivo. Reviewed by Coecke et al., 2007Re-aggregating brain cell culture (Braissant et al., 2002)
Primary dissociated culture (Bal-Price and Brown, 2001)
Immortalized human and rodent cell lines (Hong et al.,
2003; Coecke et al., 2002)
Acute Systemic Toxicity Standard cytotoxicity endpoints, e.g. MTT, NRU using non-
hepatic cell lines (e.g. 3T3), non-metabolizing cell type (e.g.
V79) cells transfected with speciﬁc CYPs (Coecke et al.,
2001), metabolic competent model (primary hepatocytes)
Can be used as part of decision-tree testing strategies for
acute systemic toxicity and TK with respect to the
requirements of the EU REACH legislation (Combes et al.,
2008). ACuteTox program to replace in vivo acute toxicity
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Table 1 (continued)
Endpoint Organ Model Comments
(Dierickx and Scheers, 2002; Clothier et al., 2006; Vignati
et al., 2005), HPCT-1E3 model (Kneuer et al., 2007), Fa32
cells, HepG2 cells (Dierickx, 2000), genetically engineered
NIH-3T3 or V79 cells (Bull et al., 2001)
testing with in vitro basal cytotoxicity models – initiated in
2005 (Clemedson et al., 2006)
Long-term toxicity Nephrotoxicity cell lines: RPTEC-TERT1 (Wieser et al.,
2008) and HK-2 (6th Framework STREP: Predictomics –
Short-term in vitro assays for long-term toxicity (Jennings
et al., 2009)
These cell lines are being used in Predict-IV
K. Schroeder et al. / Toxicology in Vitro 25 (2011) 589–604 593of a DNEL. Each chemical should be registered with ECHA, along
with information on properties, uses and safe handling practices.
If based on the current regulations, REACH will take many years
and require vast numbers of animals (the latter number is under
strong dispute and ranges between 9 million (ECHA, 2009) and
54 million (Hartung and Rovida, 2009)). Therefore, the REACH reg-
ulation challenges the chemicals industry to develop rapid, rele-
vant, cost-effective in vitro assays to reliably predict human
toxicity. In addition to drawbacks such as lack of regulatory accep-
tance another challenge for in vitro assays is that multiple models
are needed to replace one in vivo model.2.3. Pesticides
The European Food Safety Authority (EFSA) is a European
agency whose role is to provide independent scientiﬁc advice
and information in the form of opinions and technical reports to
support Community legislation and policies and to collect and ana-
lyse data allowing assessment and monitoring of risks in the food
and feed sector. The work of EFSA is mainly carried out in different
expert panels dealing with, besides other food related ﬁelds, for in-
stance with food additives, genetically modiﬁed organisms, food
contaminants, transmissible animal diseases and pesticides and
their residues. In a new regulation (EU, 2010), the EU Commission
recommended that alternative models should include in vitro and
in silico methods, as well as reduction and reﬁnement of in vivo
tests. Speciﬁcally for ADME determination, the EU Commission fa-
voured the use of in vitro models from the same species as those
used in pivotal studies and in human materials (microsomes and
intact cell systems).
A risk assessment method considering the 3Rs currently ex-
plored by the EFSA is the Qualiﬁed Presumption of Safety (QPS) ap-
proach for micro-organisms. The QPS approach is based on the
presumption that if for a taxonomic group of micro-organisms
safety concerns can be excluded, any strain of this group can be
considered as safe and that consequently further assessment (also
employing animal tests) can be waived, thus reducing unnecessary
animal tests.
In the European Union (EU) risk assessment and authorisation
of plant protection products (PPPs) was at the time of the work-
shop carried out according to the provisions laid down in Council
Directive 91/414/EEC (EFSA, 2007). This directive has been re-
placed by Regulation (EC) 1107/2009 of the European Parliament
and the Council which will be fully applicable by 14th June 2011
(EU, 2010). PPPs that are designed to control pests are toxic by def-
inition and are normally actively brought into the environment.
Therefore, extensive testing before any decision on authorisation
is mandatory. Testing requirements for the assessment of active
substances with respect to possible human health effects include
a battery of in vivo tests (acute, subchronic and chronic tests,
reproduction toxicity) and are laid down in Annex II to Directive
91/414/EEC while in Annex III testing requirements for the ﬁnal
plant protection product are listed. The same data requirements
are laid down also in the new regulation.In an opinion that was formally adopted in 2007 (EU, 2007) the
PPP and their residues (PPR) panel has provided recommendations
for a revision of the data requirements of the directive and the new
regulation, respectively. Several of these recommendations would
reduce animal testing and animal use in the future. Recommenda-
tions given are for instance:
 Considering the application of PBBK modelling for assessing
ADME.
 Waiving dermal acute tests when the oral toxicity and dermal
absorption is low.
 Waiving in vivo genotoxicity tests when in vitro tests are
negative.
 Employing the local lymph node assay for the assessment of
skin sensitisation.
 Reviewing the questionable requirement of a 1-year dog study.
 Waiving, under certain circumstances, the conduct of a carcino-
genicity study in mice.
Within the frame work of a new guidance document on the def-
inition of pesticide residues for dietary risk assessment, the PPR Pa-
nel Unit is exploring on a large scale the applicability of alternative
scientiﬁc tools not involving animal testing, like read-across and
grouping of chemicals, QSAR and also the TTC approach for the
assessment of the toxicity of pesticide metabolites that are present
in food commodities.
2.4. Cosmetics
The Scientiﬁc Committee on Consumer Safety (SCCS) is an inde-
pendent scientiﬁc committee (managed by the Directorate General
for Health and Consumer Protection of the European Commission),
which provides scientiﬁc advice to the Commission on non-food
related issues. Cosmetics legislation is different from that of other
sectors and is, across the EU, based on the Cosmetics Directive 76/
768/EEC (EU, 1976). The 6th Amendment to the Directive (EU,
1993) requires that for each cosmetic product a safety dossier is
available based upon the risk assessment of the individual ingredi-
ents (Pauwels and Rogiers, 2004) and not on that of the ﬁnal prod-
uct, as is the case in the USA. The 7th amendment (2004)
prohibited the testing of ﬁnished cosmetic products in animals.
Furthermore, a marketing ban on cosmetic ingredients tested
in vivo for genetic toxicity, acute toxicity, eye irritation and skin
irritation, came into effect on 11th March, 2009. The ban on repro-
ductive toxicity, repeat dose toxicity and TK is expected to become
effective in 2013. Whereas clear testing and marketing deadlines
(11th March 2009 and 11th March 2013) are mentioned in the leg-
islative texts, it is also clear that the scientiﬁc progress that would
allow meeting these deadlines is not yet achieved. It is therefore
urgent for the cosmetics industry to develop validated assays that
fully replace animal studies for these endpoints in the future.
Although the SCCS welcomes the use of alternative methods
once they have been validated, the Committee is confronted with
the fact that still today the majority of the results present in the
safety dossiers are based on animal studies. In particular, for active
Table 2
In silico models used for identifying speciﬁc organ toxicity and ADME properties.
Model Comment
OECD QSAR Application Toolbox Incorporates information into a logical workﬂow by grouping chemicals into chemical categories (www.oecd.org).
Evaluates the hazard based on the overall data set of the category, which must not have every chemical tested for every
endpoint. Read-across from one tested chemical to an untested chemical is carried out to ﬁll the data gaps
TOPKAT (Toxicity Prediction by Komputer
Assisted Technology)
A statistically based system consisting of a number of robust, cross-validated QSAR models (www.accelrys.com) derived
from large data sets of toxicological information from the literature. Chemicals are characterized according to structural,
topologic, and electrotopologic indices. This system contains models based on data from 1258 compounds
(www.accelrys.com) and can differentiate between irritants and non-irritants
DEREK (Deductive Estimate of Risk from
Existing Knowledge)
A knowledge based system comprising a number of structural rules (based on strongly acidic and basic features which
relate to the parent molecules) that aim to encode structure–toxicity information with an emphasis on mechanisms
(Sanderson and Earnshaw, 1991)
DSS (Decision Support System) The DSS SICRET (Skin Irritation Corrosion Rules Estimation Tool) model consists of a number of rules (known as the
Gerner rules) based on physicochemical characteristics (such as melting point, logP and aqueous solubility) to exclude
irritation, and structural alerts to include and predict corrosive chemicals (SICRET) and irritants (Saliner et al., 2007)
MEGen (Model Equation Generator) This is a free web-based PBBK model equation generator and parameter database developed at the Health and Safety
Laboratory as part of a joint industry project promoting the rapid generation of PBBK models (http://xnet.hsl.gov.uk/
megen)
ECOSAR A library of QSARs which predicts aquatic toxicity and an expert system for selecting the appropriate QSAR
OncoLogic Cancer Expert System: Predicts concern levels for cancer potential based on ‘‘knowledge rules’’
PBT Proﬁler Estimates Persistence, Bioaccumulation and Toxicity and distribution in water, soil, sediment, and air using a Level
IIImulti-media model
MultiCASE The Multiple Computer Automated Structure Evaluation (MultiCASE) program uses a special type of algorithm to
automatically identify chemical moieties that could lead to genotoxicity and deselect chemicals which lack structural
alerts (e.g. high molecular weight chemicals such as polymers and chemicals which are only exposed dermally)
ADMEWorks ADMEWorks can be used for predicting chemical and biological properties of compounds based on molecular structures
(physicochemical, topological, geometrical, and electronic properties) and data on the property of interest (Hayashi
et al., 2005)
Vitic Nexus database A chemically intelligent database, which can recognise and search for similarities in chemical structures
(www.lhasalimited.org)
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based upon the lowest ‘‘no observed adverse effect level’’ (NOAEL),
obtained either via a repeated dose toxicity test or a developmental
toxicity study. Furthermore, the dermal absorption value and the
calculated exposure level are also taken into consideration in the
MoS calculation. Together with the results from skin/eye irritation
tests, skin sensitisation assays and mutagenicity/genotoxicity
screening batteries, the safety evaluation commonly is completed.
In the cosmetic ﬁeld, speciﬁc additional studies are only per-
formed with the purpose of elucidating mechanisms and/or to re-
duce TK or toxicodynamic underlying the minimal MoS value of
100. With the exception of the in vitro dermal absorption study,
separate TK/biotransformation studies do not form key parts of
current cosmetic dossiers. This, however, does not imply that the
cosmetic sector would not be interested in the development of
such alternatives – quite the opposite. One example is the develop-
ment of sound xenobiotic biotransformation systems (e.g. appro-
priate functional cell lines) that could subsequently be used in an
integrated approach next to repeated dose toxicity studies, devel-
opmental and/or mutagenicity/genotoxicity studies and possible
alternative non-animal methods. Past experiences have shown that
in vitromethods do not deliver reliable results and, together with a
lack of a sound metabolic system, may constitute a major hurdle in
the development of relevant in vitro assay systems.
In the cosmetic area, in addition, the availability of a good
in vitro mutagenicity/genotoxicity battery is crucial. An in-depth
study of 194 SCCP dossiers between 2002 and 2006 showed that
the in vitro predictive potential alone is insufﬁcient. Indeed, in that
period 19 compounds were found positive in vitro, but negative in
the conﬁrmatory in vivo assays, meaning that these compounds
would have been lost without the overriding animal testing possi-
bility (Rogiers and Pauwels, 2008). With respect to skin sensitisat-
ion, an in vitro method that would predict the conversion of a
pro-hapten into a hapten would be a signiﬁcant improvement.
Finally and importantly, it has repeatedly been acknowledged that
examination of biotransformation and TK in general appear to be
the ideal starting point for future long-term toxicity 3R-strategies.3. Use of in vivo and in vitro assays for risk assessment by
different industry sectors
Risk assessment in all sectors usually consists of hazard iden-
tiﬁcation, dose–response assessment (together hazard character-
ization or effects assessment) and exposure assessment (which,
together with effects assessment, forms the risk characterization)
(Van Leeuwen, 2007). Animal data is used to extrapolate to hu-
mans and speciﬁcally to estimate the exposure level which would
lead to a speciﬁc level of risk (for non-threshold effects) or a
threshold below which no adverse affects are measurable (for
threshold effects). A default combined safety factor in use for
extrapolation of animal data to (sensitive) humans is 100 and
has been used by FDA since the mid-50s (Lehman and Fitzhugh,
1954). It has since been adopted by the Joint FAO/WHO Expert
Committee on Food Additives (JECFA) and by the Joint FAO/
WHO Expert on Pesticide Residues (JMPR) to deﬁne the Accept-
able Daily Intake (ADI) (Truhaut, 1991). For other chemicals (at
least in the EU) such as industrial chemicals and biocides, the
MoS is calculated using two main scaling safety factors, namely,
inter-species differences and intra-species differences (Renwick
and Lazarus, 1998). It is used to extrapolate from a group of test
animals to an average human, taking into account inter-species
differences in kinetics and dynamics and variability in human
kinetics and dynamics to account for sensitive subpopulations
(Fig. 1).
Fig. 2 is a general scheme, generated as a result of break-out
group discussions, on the use of alternative approaches used by
different industrial sectors and how they are often used as com-
pounds progress from identiﬁcation to products, along the devel-
opment pipeline. Naturally, there are a number of similar
approaches where it is not only ethical to avoid animal testing
but it makes good business sense to screen compounds for both
efﬁcacy and safety using appropriate non-animal models. The
point at which animal tests come into the research and develop-
ment process may be driven by regulation or by the lack of an
alternative for the evaluation being undertaken. It should be
Table 3
Supporting activities from industry, European Commission and Academia.
Activity Description of activities
EPAA Main objectives include mapping of past and current 3R activities to better inform the planning and prioritisation of subsequent
actions; prioritisation, promotion and implementation of future research based on the application of the 3Rs; dissemination and
implementation of best practice in the use of the 3Rs. EPAA has recognised the need for interaction between academia, industry and
regulators to ﬁnd ITS, or ‘‘building blocks’’, which are reproducible, transferable and mechanistically predictive. Major challenges in
validating alternative assays were discussed during an EPAA–ECVAMWorkshop on ‘Overcoming barriers to validation of non-animal
partial replacement methods/Integrated Testing Strategies’ in 2008 (Kinsner-Ovaskainen et al., 2009)
ECVAM ECVAM works in co-operation with other organizations to develop standardized and validated methods for regulatory purposes.
Regulators have to be conﬁdent in the alternative tests and, in order to achieve this, in vitro toxicity studies should be carried out
according to Good Laboratory Practice (GLP). The ECVAM Workshop Report concluded that the OECD documentation on GLP should
be applied as far as possible (Cooper-Hannan et al., 1999). This lead to the publication of an OECD Advisory Document in 2004, which
outlined the ‘‘Application of the Principles of GLP to in vitro Studies’’ (OECD, 2004). As an aid to the production of robust data, an
ECVAM Task Force Report provided guidance on good cell culture practice (GCCP) (Coecke et al., 2005b). ECVAM has focussed on the
use of human models
ACuteTox This project is an EU-funded project (6th Framework Programme (FP6)) focussing on the development and pre-validation of a simple
and robust in vitro testing strategy for prediction of human acute systemic toxicity. The aim is to replace animal acute toxicity tests
currently used for regulatory purposes by in vitro tests which allow for detection of bioactivated toxins. The project uses the
paradigm that acute toxicity of a compound is determined by its basal cytotoxicity. However, this may not hold for many compounds
for which acute toxicity is due to speciﬁc toxicity, rather than basal toxicity. This has been addressed in Work Package 6.1 in which
the cytotoxicity reference chemicals, as well as 5 additional compounds which require bioactivation, have been compared primary
hepatocytes (metabolically component) and HepG2 cells (relatively poor metabolic competence). Compounds which are more toxic
to hepatocytes suggest that they require bioactivation to elicit cytotoxicity. In Work Package 7 (investigating neurotoxicology,
nephrotoxicity and hepatotoxicity), different measurements of cytotoxicity were compared with the MTT assay. Following statistical
analysis and data mining, the best combinations of in vitro tests that give a relatively good correlation with in vivo (rat and human)
data were identiﬁed. Thirty-three compounds will be tested in the selected assays under blind conditions and the results will be used
retrospectively to validate the preliminary testing strategy
Predict-IV This project sets out to proﬁle the toxicity of new drugs using a non-animal-based approach integrating toxicodynamics and
biokinetics. The aims include the development of new strategies for drug safety assessment focusing on non-animal test systems.
Other goals are to deduce MoSs and identify early biomarkers in human hepatotoxicity, nephrotoxicity and CNS toxicity. Long-term
human models for non-target organ speciﬁc toxicity and bioactivation systems and co-culture models for speciﬁc toxicity are also
being evaluated. The aim is to analyse samples, using genomic, transcriptomic and metabolomic proﬁling, from each model which
have been treated with the same compound and compare outcomes from each endpoint. The compounds selected are those with
well-described toxicities and kinetics in animals and partly also in humans
OSIRIS OSIRIS (Optimised Strategies for Risk Assessment of Industrial Chemicals through Integration of Non-Test and Test Information) aims
to develop an ITS to enable a signiﬁcant increase in the use of non-testing information for regulatory purposes. One of the so-called
‘‘interlinked Research Pillars’’ focuses on exposure-informed testing (triggering and waiving). The reduction of the use of animals
could be implemented in a number of ways and some of these issues have been discussed previously (Barton et al., 2006; Creton
et al., 2009). Results from recent studies are shown in the ORISIS web site http://www.osiris.ufz.de/index.php?en=18585
START-UP 3Rs ‘‘START-UP’’ is a coordination and support action coordinated by Prof. Vera Rogiers. A number of small 3Rs projects are supported
which aim to establish a better link between academia and industry. The latest progress report is available at ftp://
ftp.cordis.europa.eu/pub/fp7/docs/alternative-testing-progress-report-2009_en.pdf
EU Directorate General (DG) for
Research
As a result of the high priority of developing alternatives to existing repeated dose systemic toxicity testing, the EU Directorate
General (DG) for Research and Colipa to formulate a speciﬁc research strategy to address this problem. Two of its main objectives are
to (1) encourage collaboration between industry and academia to gain leadership in key technology areas and (2) promote ideas by
supporting basic research at the scientiﬁc frontiers (implemented by the European Research Council). There are several FP6 projects
still running in DG RTD which apply in vitro and in silicomethods for human safety assessment. FP7 includes a signiﬁcant number of
new initiatives ranging from ITS to coordination to optimization of the use of the limited ﬁnancial resources. More information on the
on individual research projects and support actions can be found in the 2009 Progress Report on Alternative Testing Strategies http://
cordis.europa.eu/documents/documentlibrary/106691831EN6.pdf
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at early stages of development may actually reduce the overall
numbers of animal procedures that may have identiﬁed a toxico-
logical issue much later in development. Therefore reﬁnementInter-species difference    
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Fig. 1. Uncertainty factors incorporated inand reduction are often forgotten but still very important steps
in the overall 3R target.
In all sectors an initial evaluation of new chemicals is often
made based on their physicochemical properties, e.g. solubility,Intra-species difference 
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3.2
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3.2 
to the MoS used in risk assessment.
Fig. 2. Target diagram on the use of alternative approaches in the ADME safety
testing area by different industrial sectors. The target for each sector is to undertake
more extensive in silico and in vitro evaluation of new chemical entities in early
development so that fewer animal studies are needed as the development process
moves towards animal testing that is often a regulatory requirement. Although all
sectors actively pursue alternative approaches for ethical and practical reasons, the
cosmetics industry is actually prohibited from using animals for speciﬁc toxicity
endpoints. (Diagram prepared by Jon Heylings).
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corrosive effects can be made if the chemical has an ‘extreme’ pH
value (P11.5 or 62), especially if it is to be applied topically (it
may be corrosive or a skin or eye irritant, for example). In order
to screen potentially thousands of compounds, many companies
incorporate the use of in silico models (listed in Table 2).
As part of a risk assessment of possible systemic toxicity, in addi-
tion to the characterization of the hazard, the likely systemic expo-
sure of the chemical has also to be taken into account. This will
differ between industries since pharmaceutical companies usually
aim to reach a signiﬁcant target therapeutic plasma concentration
and assess the compound on a risk-to-beneﬁt basis. Since the in-
tended exposure target is potentially high, consideration of the
risk-to-beneﬁt is important in the pharmaceutical industry (more
so than thechemical or cosmetics industry) and theweightof this ra-
tiomay also differ according to the different product types (e.g. can-
cer therapy versus diabetes). For chemicals industries it is key to
assess the likely exposure under occupational conditions.
In vitro assays are used by all sectors of industry for safety test-
ing but the need for in vitro models in risk assessment will differ
according to the needs of the different industrial sectors and the
speciﬁc question that needs to be addressed. Appropriate models
of varying complexity are often used by different sectors to address
speciﬁc organ toxicity. For example, there are a number of models
used for investigating liver metabolism and toxicity which have
certain characteristics as well as limitations in their use (summa-
rised in Table 4). In vitro data may be more suitable for in-house
decision-making within an industry sector, whereas the regulatory
agency may ask for much more speciﬁc information on an effect
seen in vitro (e.g. whether a speciﬁc transporter is involved in the
clearance of a compound). Exposure-based waiving can be used
as in-house method if, e.g. an in vitro assay shows that a target or-
gan would not be exposed to a test compound, in which case, an
in vivo study would not be needed.
In the pharmaceutical industry, animal studies have to be car-
ried out for licensing of a medicinal product containing a new ac-
tive substance but in vitro assays are used for screening, drugcandidate selection and drug–drug interaction information for
Phase 1 clinical trials. ADME studies here are not necessarily con-
ducted according to regulatory legislation. Moreover, studies
which investigate the use of potential drug candidates can be per-
formed under non-GLP conditions, especially for non-standard
screening technologies, safety studies performed to support regu-
latory requirements (e.g. Investigational New Drug (IND) applica-
tions) should, in general, be GLP compliant. However, in vitro
assays performed to predict toxicity may be carried out according
to the FDA draft guidelines (FDA, 2006). These assays are included
in Table 1. The pharmaceutical industry and, on a less routine basis,
the chemical industry employ PBBK models to identify and reduce
uncertainties in risk assessment (MacGregor et al., 2001; Delic
et al., 2000). In terms of risk management, it should be kept in
mind what constitutes an acceptable risk, depending on the indus-
try and the purpose of the compounds under development.
Once an assessment of the source and likely exposure of a
chemical is addressed, the risk can be characterized as an estima-
tion of the incidence and severity of any adverse effects likely to re-
sult from actual or predicted exposure. For REACH chemicals, the
level of exposure above which humans should not be exposed
should be estimated, i.e. the DNEL (Derived No Effect Level). In
the risk characterization, the exposure of each human population
known to be, or likely to be exposed, is compared with the DNEL.
The risk to humans can be considered to be adequately controlled
if the estimated exposure levels do not exceed the DNEL. Calcula-
tion of the DNEL (Human Limit Value) involves a number of consid-
erations such as uncertainty, extrapolation or assessment factors
(inter-species, intra-species, exposure duration, route-to-route
etc.) and should not be confused with the NOAEL (usually derived
in animals). For agro-chemicals, in vitro assays can be used to com-
pare metabolites produced by mammalian cells with those pro-
duced by plants and determine whether the toxicological
evaluation of each agro-chemical sufﬁciently encompasses any
crop residues of concern.
The acceptance and validation of in vitro models is most press-
ing for the cosmetics industry. They must consider the route and
extent of exposure, since the skin is the main site of application
of cosmetics, as a result, major focus has been placed on dermal
absorption for which accepted in vitromethods are available. Other
dermal models include human reconstructed skin models for use
in genotoxicity testing (Munn et al., 2009). For other endpoints
such as skin and eye irritation, scientiﬁcally accepted methods
used in combination are being used as alternatives to animal mod-
els. In contrast to other sectors, the cosmetics industry is required
by law to replace a number of in vivo animal tests with scientiﬁ-
cally valid alternative approaches.
4. Information gained from in vitro assays
In an optimal situation, ADME/TK are cross-cutting issues that
are taken into account in all these processes, albeit not literally
or speciﬁcally required in various sector legislations. To this end,
scientiﬁcally justiﬁable – but not legally required – information
may come from in vivo as well as in vitro assays which can be used
by one or more sectors to determine ADME properties as well as
understanding mechanisms of action. Examples of information
gained from in vitro models are described below and listed in
Table 1. A major challenge is that in vitro methods are needed that
allow for a quantitative assessment of effects in vivo.
4.1. Absorption/exposure
Safety assessors from all industry sectors will need to evaluate
the exposure of a chemical to human health, whether it is intesti-
nal absorption from an orally dosed drug, systemic exposure from
Table 4
In vitro liver models and their characteristics and limitations.
Model Characteristic Advantage Limitation
Isolated perfused liver Ex vivo organ culture Complete liver enzymes and
cofactors
Fresh tissue needed
Liver architecture retained Short-term viability (2–3 h)
Closest to in vivo All liver cell types present Study of one or a few compounds only
Bile ﬂow Humans excluded
Low reduction of animal numbers
Liver slices Ex vivo tissue culture Complete liver enzymes and
cofactors
Fresh tissue needed
Most liver cell types present Limited viability (24 h)
Close to in vivo Cell–cell interactions Damaged cells at the cut surface
Marginal aeration of inner cells
Slow transport
Bile collection excluded
Cryopreservation limited
Hepatocytes Ex vivo cell culture from livers or
biopsies
Complete liver enzymes and
cofactors
Speciﬁc techniques and well-established
procedures needed
Cell culture Cryopreservation possible
Higher throughput screening
possible
Liver architecture lost
Enzyme levels decrease during culture
Batch variability (e.g. viability, attachment
efﬁciency)
Liver cell lines In vitro cell culture Good inter-experimental
reproducibility
Poor or absent enzyme expression
Cryopreservation possible Limited enzyme activities
Cell culture Suitable for high-throughput
screening
Genotype and phenotype instability
Not many adequately characterized cell lines
Sub-cellular fractions Organelle fraction suspension;
endoplasmic reticulum-bound and
cytosolic enzymes
Easy to use Microsomes contain only CYPs, FMOs and
UGTs
Suitable for high-throughput
screening
Require cofactor supplementation
Cryopreservation possible Extrapolation to in vivo limited
Induction effects excluded
Enzyme preparation Partial metabolic proﬁle
Short-term incubation
Genetically engineered cells In vitro cell culture or protein
suspension; enzymes produced in
endoplasmic reticulum of host cells
(bacteria, yeast, mammalian cell
lines or baculovirus); with or
without cofactors
Good inter-experimental
reproducibility
Limited enzyme number per experiment
Cryopreservation possible Pilot study needed
Suitable for high-throughput
screening
Short-term study
Extrapolation to the in vivo situation limited
Artiﬁcial system
Modiﬁed according to Coecke et al. (2006), Guillouzo (1998), Plant (2004) and Pelkonen et al. (2004).
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cide. Whereas the pharmaceutical industry is aiming to have good
systemic exposure (high bioavailability), the chemical, pesticide
and cosmetics sectors are likely to develop chemicals which are
poorly absorbed. A number of cell lines, such as Caco-2, are rou-
tinely used to determine intestinal absorption. When used as part
of a simulation model that takes into account solubility and disso-
lution in the gastrointestinal tract as well, they give a good predic-
tion as to the extent of absorption (Thomas et al., 2008). Likewise,
cell lines have been employed to predict penetration across the
blood brain barrier, although these models still require some fur-
ther development. The most relevant route of exposure for cosmet-
ics, industrial chemicals and pesticides is the skin (although
exposure via inhalation and the oral route can be very relevant
as well), for which static or ﬂow-through diffusions cell models
have been standardized (as least in part) for use with human, pig
and rat skin in OECD and EU context (OECD TG 428, (SANCO,
2004)). Moreover, there is on-going revision of the current guid-
ance document on dermal absorption (SANCO, 2004).
4.2. Metabolic pathway identiﬁcation and clearance
The liver is the main site of metabolism of xenobiotics and
therefore the majority of in vitro models to determine metabolic
pathways and clearance are hepatic (hepatocytes, S9, microsomesetc., Tables 1 and 4). For the potential occupational exposure of
chemicals via the dermal route, metabolism in the skin is of impor-
tance since it has been shown to possess a number of drug metab-
olizing enzymes (Oesch et al., 2007). In vitro models used to
evaluate skin metabolism include normal keratinocytes, cell lines
such as HaCaT cells and ex vivo human skin (Table 1). For the phar-
maceutical industry, knowledge of the enzymes involved in the
metabolism of a compound can provide information of the likeli-
hood of drug–drug interactions, possible problems due to polymor-
phic enzymes, disease, gender and age; and potential reactive
metabolites. So-called ‘‘phenotyping’’ information can be used to
provide individualized health care and stratiﬁed clinical trials.
For cosmetics, human liver microsomes have been used to screen
hair dyes for their potential to form reactive intermediates rather
than carrying out in vivo assays which are also more labour inten-
sive and expensive (Skare et al., 2009).
Many researchers focus on the cytochrome P450s (CYPs) since
these are the major phase 1 enzymes responsible for the metabo-
lism of the majority of pharmaceuticals on the market (Zuber
et al., 2002). However, there are other non-CYP enzymes which
may also metabolise compounds, such as the phase 1 alcohol dehy-
drogenases (Kollock et al., 2008)) and the phase 2 enzymes, sul-
fotransferases (SULTs), UDPGA-glucuronosyltransferases (UGTs)
and glutathione S-transferases (GSTs) (Evans and Relling, 1999).
It is important to include phase 2 enzymes such as GSTs in
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uation. In many cases phase 2 enzymes can detoxify substances
and/or their phase 1 metabolites (e.g. paracetamol toxicity
(Schnackenberg et al., 2008)). Identiﬁcation of the enzyme(s) in-
volved in the metabolism of a compound and understanding how
metabolism may vary across and within species and across human
subpopulations, e.g. poor metabolizers versus extensive metaboliz-
ers (Bogni et al., 2005), is very important for risk assessment
(choice of test-species and possible use of a larger intra-species
extrapolation factor). Another important use of in vitro metabolic
studies is the use of these data to conﬁrm the MoS (see Section 3).
The use of a general 3.2 kinetic factor reﬂecting inter-individual
variation may not cover metabolism by poor metabolizers or ex-
tremes of ages (Renwick and Lazarus, 1998; Dorne et al., 2002,
2003; Dorne and Renwick, 2005); therefore, the kinetic factor can
be conﬁrmed or adjusted according to the metabolic phenotype.4.3. Selection of most relevant species
Traditionally, the evaluation of species differences in metabo-
lite formation has not been considered on a routine basis, mainly
due to the uncertainty of the contribution of metabolites to the
toxic effect. However, it is now evident that species differences
in drug metabolizing enzymes can inﬂuence the toxicity of a
compound across species (Uehara et al., 2008). Therefore, there
is a need to carry out TK studies on rodent and non-rodent spe-
cies in order to decide on the most relevant test-species for pos-
sible human effects testing. For example, according to the FDA
guidelines (FDA, 2005), if a metabolite represents more than
10% of parent compound in human (deﬁned as a major metabo-
lite), then it should be present in the animal species tested. This
emphasises the importance of establishing major metabolites
produced by different species using in vitro assays so that they
can be covered in animal toxicity studies. This line of guidance
is also recommended by the EU Commission (EU, 2010). Follow-
ing on from this, in order to evaluate non-clinical animal toxicol-
ogy studies, the systemic exposure of the drug (quality, i.e. parent
and/or metabolites, as well as quantity, i.e. extent and/or rates of
formation) should be considered and compared between the test-
species and humans (i.e. species-speciﬁc metabolism). This
comparison is reasonable if the metabolic pathways are similar,
however, in rare cases, if in vitro assays suggest that major
metabolites produced in humans are not evident in animals, then
further investigations into the toxicity of the metabolite are
necessary. If it can be established that at least one animal test-
species produces major metabolite(s) observed in humans, it
can be assumed that the metabolite’s contribution to the overall
toxicity assessment has been taken into account. The use of
in vitro assays, especially in early compound development, allows
for selection of compounds and, when possible, the most suitable
pre-clinical species, as well as ﬂagging up compounds that may
require additional toxicity studies to evaluate the contribution
of the metabolites to the toxic effects (Coecke et al., 2005b).4.4. Drug–drug interactions in pharmaceutical safety evaluation
Drug–drug interactions are most relevant to the pharmaceutical
industry since often more than one drug is purposefully given at
therapeutic doses to treat multiple symptoms/causes of illness
(i.e. polypharmacy). Unfortunately, one drug may alter the phar-
macokinetics of the co-therapy drug and result in either the loss
of efﬁcacy or increased toxicity of the latter. Metabolic inhibition
of drugs can be predicted using human liver microsomes whereas
human hepatocytes are considered to be the ‘‘Gold Standard’’ for
predicting metabolic induction (Table 1). Knowledge of potentialdrug–drug interactions is a vital part of the candidate (de)selection
process as well as aiding in the design of clinical interaction trials.
4.5. Mechanistic understanding
Signiﬁcant progress has been made in the understanding of cel-
lular-response networks, i.e. a network of pathways involving a
complex biochemical interaction of genes, proteins, and small mol-
ecules that maintain normal cellular function. Advances in our
knowledge of the pathways are allowing researchers to investigate
how they are altered by environmental agents and ultimately lead
to toxicity. The US National Research Council (NRC) report in 2007
called for more human-cell-based, high-throughput assays that
encompass a multitude of toxicity pathways and in response,
NIH (National Institutes of Health) and EPA have entered into a for-
mal collaboration known as Tox21 (Tox21, 2008). Their aims are to
identify mechanisms of chemically-induced biological activity, pri-
oritize chemicals for more extensive toxicological evaluation, and
develop more predictive non-animal based models of in vivo bio-
logical response. Hopefully, this research will lead to toxicity mod-
els that are more scientiﬁc and cost-effective as well as models for
risk assessment that are more mechanistically-based. Despite the
advances, the resulting mechanism-based assays need validation
or at least profound scientiﬁc evaluation before they can be used
routinely. Often, the appropriate prediction evaluation occurs in
parallel with assay development and ultimately leads to the
streamlining of the assay. Parameters such as stability of solutions,
proteins or even cell lines should be checked and standardized.
Incubation times, storage, robustness (replicates for statistical
analysis) are also some of many considerations companies make
when validating assays (McGee, 2006).
5. Recommendations from the workshop for in vitro assays
The main priority for all industry sectors is the safety of the
products and thus for people, animals and the environment and
doing this with a reasonable the number of animals used and, in
the case of the cosmetics industry, to replace in vivo assays en-
tirely. Some of the priorities were discussed in break-out groups
(each containing representatives from academia and industry and
in some, representatives from regulatory bodies) from the work-
shop and are listed below. The sector(s) to which the priority ap-
plies most is shown in brackets. Topics that were discussed were
not necessarily the views of all those who participated.
5.1. Apply considerations for in vitro assays (all sectors)
Through discussions in the workshop, it was concluded that in
order to interpret in vitro data, a number of considerations need
to be made which include:
 Are in vivo and in vitro concentrations the same and is the
in vitro concentration relevant to in vivo?
 Is the effective concentration the same as the concentration
added to the in vitro system? Is the effective concentration
in vitro translated correctly to the in vivo concentration?
 What are the volatility and binding properties (to plastic sur-
faces and/or to microsomal/cellular proteins) of the compound?
This in turn affects the concentration to which the cells are
exposed. In order to determine the free fraction of compound,
solid phase micro extraction can be used (Pawliszyn, 1995; Vaes
et al., 1996).
 What is the free concentration of test compound in incubation
mediumcontaining different concentrations of serum? The pres-
ence of serum can affect the free fraction of a compound asmuch
as reducing it to 1000th of the nominal concentration added.
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assays focus on one organ, rather than the animal/human as a
whole. Therefore, inﬂuences of other organs are not incorpo-
rated into the model and may cause an under- or over-predic-
tion of a toxic effect. Section 4.1 describes how at least the
distribution into multiple organs can be predicted using
(physiologically-based biokinetic) PBBK modelling approaches.
 Consideration of the phenotype: A pre-screening characteriza-
tion of cell lines, especially if they lack speciﬁc bioactivating/
detoxiﬁcation enzymes, should be carried out in order to inter-
pret resulting data. A common understanding of HepG2 cells is
that they have a low metabolizing capacity; however, there are
reports of these cells having comparable enzyme activities to
primary human hepatocytes (Westerink and Schoonen,
2007a,b) and such activities may be due to the source (and
therefore sub-clones) and the type of basal medium used to cul-
ture and passage them (which have been shown result in differ-
ent phase 1 and 2 enzyme activities of HepG2 cells (Hewitt and
Hewitt, 2004)).
 Consider uncommon effects: Predictive models are based on
certain assumptions and known common chemical and physio-
logical processes and, as a result, may miss certain effects. For
example, prediction of accumulation of test compounds in bone
using in vitro assays has not been described so far.
5.2. Standardize and promote in vitro assays (all sectors)
There are many variables in metabolism assays which may af-
fect their outcome; therefore, harmonization of these assays is
needed. The harmonization of toxicity tests according to OECD
guidelines began in the early 1980s. In addition the testing of the
safety and efﬁcacy of drugs is harmonized by the International
Conference on Harmonisation (ICH). This has led to the effect of
not just standardizing tests but reducing the number of animals
used, since regulatory agencies around the world now accept the
results of a test conducted according to such guidelines. Neverthe-
less, researchers have to work hard to convince regulators and the
scientiﬁc community that some in vitro/in silico methods are sufﬁ-
ciently reliable to be used, albeit not yet for systemic toxicity end-
points. It was felt that stronger involvement of regulators in the
early stages of the process should be encouraged so that it can
be clariﬁed through dialogue what information is needed for an as-
say to be validated. Additionally, the perception, or weight, of the
information from in vitro assays should be correctly assessed and
communicated between the researchers and regulators.5.3. Avoidance of false positives (all sectors)
Care must be taken not to be ‘‘overly-efﬁcient’’! For one com-
pany, due to efﬁcient in-house de-selection of test compounds,
there were no positive genotoxic compounds in in vivo studies.
Since there are false positive results from single and combined
in vitro genotoxicity assays, de-selection of all positive responses
in these assays may prevent the development of promising non-
genotoxic compounds. Negative outcomes in in vitro genotoxicity
assays (which exhibit high sensitivities) are accepted by regulatory
agencies; however, this is not the case for other endpoints such as
skin irritation. One Colipa (European Cosmetic Toiletry and Per-
fumery Association) project in progress is to reﬁne current assays
to avoid generation of false positives (project entitled ‘‘Reduction
in the ‘‘false positive’’ rate of in vitro mammalian cell genotoxicity
assays’’, co-sponsored by Colipa, ECVAM and UK NC3Rs); likewise,
the FDA is striving for highly predictive systems to avoid false
positives.5.4. Mechanism-based toxicity assays should be further developed and
validated (all sectors)
Known toxic and adverse effects should also be deﬁned for the
kidney, heart, lung, CNS, immune system, adrenal and thyroid
glands (endocrine disruptors). Information on known substances
developed by the pharmaceutical and, if possible, other industries
should be collected. This will help develop QSAR models and new
assays (including active transport, signalling).5.5. Actions related to in vitro assays (all sectors)
Workshop participants suggested two actions which may aid
the interpretation of data generated from in vitro assays, such
as:
 Integration of information from different models: Integration of
data from separate organ in vitro assays may provide a better
overview of toxicity. For example, the contribution of gut bacte-
ria may be incorporated into an absorption model to allow the
prediction whether a compound is (re)absorbed from the intes-
tine as parent or metabolite followed by possible further metab-
olism by another organ.
 Evaluation of assays: Performance assessment and evaluation
of in vitro assays is needed with appropriate controls (e.g. posi-
tive, negative and reference compounds) to conﬁrm that the
assay is functioning. For example, a cytotoxicity assay should
include a positive compound which causes signiﬁcant cytotox-
icity (up to 100%) so that the assay can be shown to be sensitive.
Likewise, an enzyme induction study should include a vehicle
and positive control for the enzyme (e.g. CYP or phase 2
enzymes) under investigation to compare the potency of the
induction effect of a test chemical and assess the dynamic range
of the induction capacity of the test system. Contract Research
Organisations usually do not validate in vitro assays that are
not requested on a routine basis. A number of specialised assays
are routinely used and these are often optimized in-house.
Lastly, the perception of ‘‘validation’’ maybe different between
companies and regulatory bodies.
6. Information gained from in silico models
A number of QSAR models exist (shown in Table 2) which can
be used to prioritize chemicals and compare large numbers of
chemicals using standardized criteria. Other mathematical models
based on ADME properties are referred to as physiologically-based
biokinetic (PBBK) models and are synonymous with physiologi-
cally-based pharmacokinetic (PBPK) models and physiologically-
based TK (PBTK) models. The prediction of in vivo PK parameters
such absorption, ﬁrst pass effects and metabolism has been suc-
cessfully demonstrated using the SimCyp PBPK model, which is a
population-based simulator using physicochemical, in vitro and in
silico data (www.simcyp.com). In addition to PK prediction models,
mathematical ADME models have been developed to assess TK
properties (the effect of the chemical on the body) to address the
3R agenda (Bouvier d’Yvoire et al., 2007). The most predictive are
those which are capable of integrating known physiochemical
and chemical-speciﬁc in vivo, in vitro as well as in silico (QSAR) data
(Blaauboer, 2003). A new paradigm is that toxicity is determined
by the critical concentration and time of exposure to the critical
compound (or metabolite) at the critical site of action of the com-
pound. Biokinetics is an important part of this paradigm. PBBK
models take into account the fact that organs are linked together.
Knowledge of in vitro kinetics can be combined with in vitro toxi-
codynamic data and incorporated into a model to predict in vivo
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in vitro data on neuronal toxicity was known (DeJongh et al., 1999).
To date, ADME software packages, although showing promising
predictive capacities, especially for absorption and distribution,
have not yet been sufﬁciently validated and still require improve-
ments. A report of an expert meeting organized by COST B15 that
reviewed the use of QSAR in drug screening (Boobis et al., 2002)
suggested that predictions using QSAR are no worse than those
made using in vitro tests, and have the added advantage that they
need signiﬁcantly less investment in technology, resources and
time. The report went onto describe a lack of conﬁdence in these
approaches and that more effort should be made by the software
producers towards more transparency, in order to improve the
conﬁdence of their consumers. It was also felt that controlled ac-
cess to data from pharmaceutical companies would help to vali-
date the models.
7. Recommendations from the workshop for in silico assays
7.1. More extensive use of QSAR by all industry sectors
If QSAR is used as the ﬁrst step in risk assessment, then com-
pounds that are ﬂagged up as toxic can be de-selected, thus provid-
ing a 3Rs and cost-effective screening process. The workshop
recommended that the basic parameters of the chemical should
be considered (e.g. physicochemical properties) as well as its par-
titioning into the tissues (indicated by the octanol:water partition
coefﬁcient versus the fat:blood partition coefﬁcient) and the phys-
iology of the organ (e.g. structure, blood ﬂow, metabolic capacity,
etc.). In addition, there should be more data generated to add to
the predictive power of models.
7.2. Further development of PBBK models (all sectors)
Further developments should combine in vitro and in silico data
to feed PBBK models. To this end, increased efforts are needed to
develop medium throughput systems to establish absorption (e.g.
Caco-2), partitioning coefﬁcients and metabolic parameters for
the most important metabolizing organs, i.e. liver and skin. The
use of publicly available tools such as the Model Equation GENer-
ator (MEGen, http://xnet.hsl.gov.uk/megen, see Table 2) should be
encouraged. Resulting PBBK models can be used to prioritize
in vitro development projects. In order for a prediction model to
be built, the extrapolation between the concentration of a com-
pound in the incubation medium in vitro and the equipotent plas-
ma concentration is a crucial step, involving predictive TK
modelling. In this modelling approach, the metabolism of the com-
pound should be taken into account, especially if it is rapidly
metabolized and the nominal in vitro concentration is not constant.
Drawbacks of in vitro models are that they have been developed
mainly for screening purposes by the pharmaceutical industry
and are not validated for certain categories of industrial chemicals.
Therefore, training with the latter compounds and taking into ac-
count uncertainty is needed.
8. Recommendations by the workshop for reﬁning and
reducing in vivo assays
8.1. Microdosing (pharmaceutical sector)
This methodology allows for the determination of human phar-
macokinetics of test compounds administered at doses much lower
than the expected pharmacologically effective or toxic levels (FDA,
2008). Microdosing has been used as part of human drug clinical
testing to evaluate drug ADME (Coecke et al., 2005b) but has not
been widely accepted for testing chemicals. This is not used uni-versally and is done on a case-by-case basis. This technology, once
installed is cost-effective to study new chemical entities and has
the advantage of requiring only very low doses of radiolabelled
compounds. One limitation to this technology is that the dose
has to be lower than 100 lg, thus if this is signiﬁcantly different
from the therapeutic dose and the pharmacokinetics proﬁle is dif-
ferent, then the low dose pharmacokinetics data may have de-
creased relevance compared to the toxic/effective concentration.
Another disadvantage of this method is that humans are purposely
exposed to radiation for biomedical research and its use should
therefore be justiﬁed (as recommended by the International Com-
mission of Radiation Protection in Publication 62 (ICRP, 1991)).
There are radiation dose constraints for volunteers under different
conditions and these are discussed in the recommendations from
the ICRP (ICRP, 2007).
8.2. Incorporation of additional endpoints (chemical sector)
In order to reﬁne and improve existing in vivo study types, as
well as reduce the number of animals used, for chemical testing,
it was recommended to increase information gained from one
study by incorporating additional endpoints into the study, e.g.
using peripheral blood for metabolomics and the micronucleus
(MN) test. It is noted that inclusion of more endpoints, e.g. kinetics,
may be difﬁcult to implement for small animals, e.g. mice. In addi-
tion, inclusion of positive controls for each endpoint may mean ex-
tra animals are needed, although, for some endpoints which have
sufﬁcient historical data, such as the in vivoMN test, additional po-
sitive controls are not an absolute requirement.
8.3. Issues in information sharing (all sectors)
The different industry sectors have generated a vast amount of
data using similar models; however, the sharing of this data across
sectors has not been as fast ﬂowing. The workshop recommended
the sharing of in vivo data, coordination and information exchange
between research projects and sectors. Companies should be
encouraged to share in-house additional data from long-term stud-
ies so that in vivo studies are not unnecessarily duplicated and in
silico/in vitro methods can be validated.
9. Proposed actions from the ADME workshop to develop
further alternative models and the 3R concept
9.1. Immediate actions
 Assess promising ADME/PBBK approaches which (a) have been
entered into the EPAA in-house methods database or directly
via member companies (internal) and (b) are available from
false positive projects or others (external).
 Establish an expert panel, including users, developers and regu-
lators, that deﬁnes the testing scope for the potentials and lim-
itations of the models with a set of chemicals.
 Organize a series of follow-ups (with EPAA members, regulators
and external stakeholders) to discuss the results and identify
gaps and recommend ways forward.
 To engage the help of ADME experts from the member
companies.
9.2. Additional actions
 Expert follow-up meeting: Review of developments and
changes in the last three years with a focus on replacement/cos-
metics (Eskes and Zuang, 2005). Participants should include the
previous ECVAM panel, the EPAA workshop participants and
selected participants from other sectors.
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from different sectors to discuss the potential role of ADME con-
cepts for the 3Rs, and make the link to the EPAA.
 EPAA could invite industries to provide regulators with case
studies to clarify/identify (minimal) regulatory requirements.
This should include the use of ADME data to allow/support
safety decision-making; proof-of-concept.
 EPAA could call industry members and other contributing par-
ties to make use of the MEGen database and share data on
selected compounds (e.g. form consortium)
 EPAA to assess if creating a ‘‘single portal’’ would be useful
(ECVAM database, EPAA database, TSAR website etc.).
 Drafting of a decision paper by the ECHA (in preparation) on the
testing proposal provided by companies which will then be dis-
tributed to national regulators for consultation. REACHprovides
more ﬂexibility which might change mindset of regulators.
ECHA has avery strong role in this process, whereas scientiﬁc
committees (e.g. the SCCP) have a different, advisory role.
10. Conclusions
Although alternative ADME and toxicodynamics testing ap-
proaches have been used for decades, their application to safety
testing strategies is of increasing importance, especially in light
of new regulations with respect to chemical testing. It is recognised
that the current in vitro metabolism models need improvement to
offer more reliable information that is usable in safety assessment.
To address this issue, an EPAA workshop was held in Duesseldorf in
November, 2008, and brought together representatives from the
pharmaceutical, chemical and cosmetic industries with those from
(inter)national regulatory agencies. There are many alternative ap-
proaches used by different industrial sectors as compounds pro-
gress from identiﬁcation to ﬁnal products. A number of non-
animal approaches not only allow for ethical testing but make good
business sense in screening compounds for both efﬁcacy and
safety. The point at which animal tests come into safety assess-
ment may be driven by regulations or by the lack of an in vitro
model. Strategies that involve a small number of animals at early
stages of development may also reduce the overall numbers of ani-
mal-based assays much later in development. Therefore reﬁne-
ment and reduction are evenly important challenges in the
overall 3R target in the ADME area. In vitro systems that reﬂect cer-
tain aspects of the ADME (and effects) process can be very helpful
in the safety assessment process as well as the 3R principal; but, on
the other hand, many in vitro systems have their pitfalls, especially
with respect to an insufﬁcient reﬂection of the integrated in vivo
physiological ADME conditions and a lack of fully validated assays.
The recommendations proposed by representatives from different
sectors and companies, which apply to all sectors, to propel the
use of in vitro alternatives in the ﬁeld of risk assessment are sum-
marised below:
 Generate open web-based database on in vivo kinetic
parameters.
 Industry data that are already available could be collected in a
central database to beneﬁt all sectors.
 Coordinate effort before generating new data.
 Expand Applicability Domains of in silico tools.
 Expand Applicability Domains of in vitro tools and develop new
in vitro tools.
 Obligatory inclusion of blood sampling for TK purposes during
toxicity studies.
 Investigate increased use of human low dose kinetics.
 Microdosing.
 Biomonitoring.The workshop concluded that these assays still need to be im-
proved but that it may be achieved by stakeholders from different
sectors sharing data so that universal agreement is reached for har-
monization of alternative approaches. Major international project
funding programs are on-going to help develop, validate and har-
monize in vitro tests and lead to their use as part of the risk assess-
ment of chemicals.Conﬂict of interest
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